MRI Prostate Spectroscopy, also known as MR Spectroscopic Imaging (MRSI) of the prostate, is an innovative method of magnetic resonance imaging that not only measures the shape of the prostate but also the chemical makeup of prostate tissue. Normal MRI imaging gives detailed information about the prostate and surrounding tissues, while spectroscopy helps determine the presence of benign or abnormal tissue based on metabolic markers.

It is a functional imaging method that is especially useful in the diagnosis of prostate cancer, evaluation of tumour malignancy and aggressiveness, as well as its targeted biopsy and therapy. MR spectroscopy can yield molecular information through the measurement of relative concentrations of metabolites (citrate, choline, creatine, etc.), that supplement structural information from MRI.

Principle of MR Spectroscopy in the Prostate

Healthy and diseased prostate tissues contain characteristic metabolites:

Citrate

Normally high in healthy prostate tissue due to active citrate secretion.

Choline

A marker of cell membrane turnover that increases in malignancy.

Creatine

Represents energy metabolism and may show mild alterations in disease.

Polyamines

Typically present in healthy prostate tissue and reduced in cancer.

In prostate cancer, citrate levels generally decrease while choline levels increase, resulting in an elevated choline-to-citrate ratio, which reflects altered cellular metabolism in malignant cells.

MRI Spectroscopy Parameters

Voxel Size

Small enough to localize abnormalities while maintaining adequate signal quality.

Echo Time (TE)

Intermediate TE values are commonly used to minimize overlap between metabolite peaks.

Repetition Time (TR)

Adjusted to balance image quality and acquisition time.

Volume of Interest (VOI)

Carefully selected to cover the prostate gland while avoiding contamination from surrounding tissues.

Interpretation of Findings

Normal Spectrum

• High citrate peak
• Moderate creatine peak
• Low choline peak

Suspicious Spectrum

• Low or absent citrate
• Elevated choline
• Increased choline-to-citrate ratio

Cancer Grading

Higher choline-to-citrate ratios are often associated with higher Gleason scores, helping in non-invasive tumor grading.

Benign Prostatic Hyperplasia (BPH)

May show variable metabolic patterns depending on glandular enlargement or inflammation.

Advantages of MRI Prostate Spectroscopy

• Performs a metabolic scan that yields additional information that goes beyond the scope of the traditional image-based scan.
• Enhances the identification and pinpointing of prostate cancer.
• Can decrease the number of unnecessary biopsies.
• Enhances staging accuracy.
• Works collaboratively with the target group to formulate plans for targeted therapy.
• Include for follow-up and treatment monitoring.

Limitations

• Needs specialized equipment and knowledge.
• The MR exam took longer than a routine MRI exam.
• The insertion of the endorectal coil may be uncomfortable.
• Vulnerable to embarrassing bowel sounds - may have both motion and bowel artifact.
• The post-treatment interpretation may be difficult because the tissues affected by the treatment will have different metabolism.

Integration with Multiparametric MRI (mpMRI)

MRI Prostate Spectroscopy is part of multiparametric MRI (mpMRI), which involves combining:

• T2W-Anatomy.Anatomy is done with T2-weighted imaging.
• To evaluate tissue cellularity with diffusion weighted imaging (DWI).
• Dynamic contrast-enhanced imaging (DCE) of vascularity.
• Metabolic analysis by means of spectroscopy.

This dual approach helps achieve greater diagnostic security and better localization of the lesion.

Clinical Applications

Primary Diagnosis

Useful in patients with elevated PSA levels and equivocal MRI findings by detecting metabolic changes characteristic of cancer.

Tumor Localization

Helps guide targeted biopsies toward the most suspicious regions.

Treatment Selection

Assists in deciding between focal therapy and more extensive treatment options.

Active Surveillance

Enables monitoring of low-risk prostate cancer patients for early metabolic signs of progression.

Post-Treatment Monitoring

Detects biochemical recurrence earlier than structural imaging changes.

Future Developments

Higher field strengths of the MRI, such as 3T MRI, are providing better quality and more accurate prostate spectroscopy, as are the developments of new MRI coils. Integration with AI could yield further enhancements for automated lesion detection and quantification of metabolites. Novel metabolic imaging agents could also be incorporated with spectroscopy into further developed approaches for the characterization of cancers in the future.

Conclusion

MRI Prostate Spectroscopy is an advanced functional imaging technique that helps to give additional information on tissue metabolism, complementary to the conventional prostate MRI. It is important for the diagnosis and characterisation of prostate cancer, determination of tumour grade, planning of therapy, planning targeted biopsy, and post-treatment management. It can be used in conjunction with multiparametric MRI to provide a more accurate diagnosis of prostate disease and to help inform patient-specific care.